Pipeline

Program Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Post Market Commercial Rights
Internal Programs
Etrasimod (APD334)
Optimized Activity S1P Receptor Modulator
Ulcerative Colitis (UC)

50%

Arena: Worldwide
Dermatologic Extraintestinal Manifestations in IBD

44%

Arena: Worldwide
Pyoderma Gangrenosum

44%

Arena: Worldwide
Primary Biliary Cholangitis

41%

Arena: Worldwide
Ralinepag (APD811)
Prostacyclin (IP) Receptor Agonist

Pulmonary Arterial Hypertension (PAH)

58%

Arena: Worldwide
APD371
Highly Selective Full Agonist to CB2
Crohn’s Pain

41%

Arena: Worldwide
Partnered Programs
BELVIQ and BELVIQ XR
Weight Loss Approved: CVOT Ongoing

98%

Eisai: Worldwide
Nelotanserin
5-HT2A Inverse Agonist
Visual Hallucinations in Lewy Body Dementia

50%

Axovant: Worldwide
REM Sleep Behavior Disorder in Dementia with Lewy Bodies

41%

Axovant: Worldwide
Undisclosed Orphan GPCR
CNS

15%

Boehringer Ingelheim: Worldwide

Program Indication Phase Commercial Rights
Internal Programs
Etrasimod (APD334)
Optimized Activity S1P Receptor Modulator
Ulcerative Colitis (UC) Ph2b Arena:
Worldwide
Dermatologic Extraintestinal Manifestations in IBD Ph2a Arena:
Worldwide
Pyoderma Gangrenosum Ph2a Arena:
Worldwide
Primary Biliary Cholangitis Ph2a Arena:
Worldwide
Ralinepag (APD811) Prostacyclin (IP) Receptor Agonist
Pulmonary Arterial Hypertension (PAH) Ph2b Arena:
Worldwide
APD371 Highly Selective Full Agonist to CB2
Crohn’s Pain Ph2a Arena:
Worldwide
Partnered Programs
BELVIQ and BELVIQ XR
Weight Loss Approved: CVOT Ongoing Market Eisai: Worldwide
Nelotanserin 5-HT2A Inverse Agonist
Visual Hallucinations in Lewy Body Dementia Ph2 Axovant:
Worldwide
REM Sleep Behavior Disorder in Dementia with Lewy Bodies Ph2 Axovant:
Worldwide
Undisclosed Orphan GPCR
CNS Pre-Clin Boehringer Ingelheim:
Worldwide
Clinical Trial Publications Expanded Access Policy